CD8A and neoplasm: Correlative analyses reveal that patients with durable clinical benefit have increased CD8 + T cell and B cell proximity to tumor cells, alongside tertiary lymphoid structures, suggesting methylation-driven immune cell distribution as a predictor of ICI success.